Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group.
Maverakis E, Wang EA, Shinkai K, Mahasirimongkol S, Margolis DJ, Avigan M, Chung WH, Goldman J, La Grenade L, Pirmohamed M, Shear NH, Tassaeeyakul W, Hoetzenecker W, Klaewsongkram J, Rerkpattanapipat T, Manuyakorn W, Yasuda SU, Sharon VR, Sukhov A, Micheletti R, Struewing J, French LE, Cheng MY. Maverakis E, et al. Among authors: yasuda su. JAMA Dermatol. 2017 Jun 1;153(6):587-592. doi: 10.1001/jamadermatol.2017.0160. JAMA Dermatol. 2017. PMID: 28296986 Free article.
Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
Goldman JL, Chung WH, Lee BR, Chen CB, Lu CW, Hoetzenecker W, Micheletti R, Yasuda SU, Margolis DJ, Shear NH, Struewing JP, Pirmohamed M. Goldman JL, et al. Among authors: yasuda su. Eur J Clin Pharmacol. 2019 Aug;75(8):1135-1141. doi: 10.1007/s00228-019-02670-9. Epub 2019 Mar 27. Eur J Clin Pharmacol. 2019. PMID: 30918988 Free PMC article.
Correction to: Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement.
Goldman JL, Chung WH, Lee BR, Chen CB, Lu CW, Hoetzenecker W, Micheletti R, Yasuda SU, Margolis DJ, Shear NH, Struewing JP, Pirmohamed M. Goldman JL, et al. Among authors: yasuda su. Eur J Clin Pharmacol. 2019 Sep;75(9):1331. doi: 10.1007/s00228-019-02710-4. Eur J Clin Pharmacol. 2019. PMID: 31254013
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. Huang SM, et al. J Clin Pharmacol. 2008 Jun;48(6):662-70. doi: 10.1177/0091270007312153. Epub 2008 Mar 31. J Clin Pharmacol. 2008. PMID: 18378963 Review.
Olanzapine-induced rhabdomyolysis.
Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Rosebraugh CJ, et al. Among authors: yasuda su. Ann Pharmacother. 2001 Sep;35(9):1020-3. doi: 10.1345/aph.10370. Ann Pharmacother. 2001. PMID: 11573848
22 results